Toyota|$17.85 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.14 (¥4,142)-1.64%▼ (in JPY terms)
SoftBank|$22.40 (¥3,549)-10.83%▼ (in JPY terms)
MUFG|$20.35 (¥3,224)-6.52%▼ (in JPY terms)
Keyence|$440.27 (¥69,750)-3.65%▼ (in JPY terms)
Nintendo|$51.62 (¥8,178)-7.91%▼ (in JPY terms)
NTT|$1.01 (¥160)-2.85%▼ (in JPY terms)
Takeda|$41.41 (¥6,560)-4.76%▼ (in JPY terms)
Tokyo Electron|$52.16 (¥8,263)-5.60%▼ (in JPY terms)
Recruit|$107.31 (¥17,000)-5.61%▼ (in JPY terms)
ITOCHU|$14.15 (¥2,241)-6.45%▼ (in JPY terms)
Honda|$11.56 (¥1,831)-5.69%▼ (in JPY terms)
Shin-Etsu|$33.53 (¥5,312)-6.69%▼ (in JPY terms)
Tokio Marine|$3.60 (¥570)-5.97%▼ (in JPY terms)
Fast Retailing|$492.03 (¥77,950)-3.79%▼ (in JPY terms)
Toyota|$17.85 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$26.14 (¥4,142)-1.64%▼ (in JPY terms)
SoftBank|$22.40 (¥3,549)-10.83%▼ (in JPY terms)
MUFG|$20.35 (¥3,224)-6.52%▼ (in JPY terms)
Keyence|$440.27 (¥69,750)-3.65%▼ (in JPY terms)
Nintendo|$51.62 (¥8,178)-7.91%▼ (in JPY terms)
NTT|$1.01 (¥160)-2.85%▼ (in JPY terms)
Takeda|$41.41 (¥6,560)-4.76%▼ (in JPY terms)
Tokyo Electron|$52.16 (¥8,263)-5.60%▼ (in JPY terms)
Recruit|$107.31 (¥17,000)-5.61%▼ (in JPY terms)
ITOCHU|$14.15 (¥2,241)-6.45%▼ (in JPY terms)
Honda|$11.56 (¥1,831)-5.69%▼ (in JPY terms)
Shin-Etsu|$33.53 (¥5,312)-6.69%▼ (in JPY terms)
Tokio Marine|$3.60 (¥570)-5.97%▼ (in JPY terms)
Fast Retailing|$492.03 (¥77,950)-3.79%▼ (in JPY terms)

admin

2026-10-27 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical Factory has launched a new product, "Hynex® Egel 1.5," a concentrated liquid food with a calorie concentration of 1.5 kcal/mL, designed to accommodate dietary restrictions on intake and fluid intake.”

by

2026-10-27 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical Factory has launched a new product, "Hyn … 続きを読む

2026-10-27 DAIICHI SANKYO COMPANY,LIMITED “Notice of Partial Approval for Enhertu® (trastuzumab deruxtecan) Regarding Postoperative Drug Therapy for HER2-Positive Early Breast Cancer in the EU (263.1KB) PDF file will be displayed in a new window.”

by

2026-10-27 DAIICHI SANKYO COMPANY,LIMITED “Notice of Partial Approval for Enhertu® (trastuzumab deruxtec … 続きを読む

2026-10-27 Astellas Pharma Inc. “VEOZA™ (fezolinenant) has been submitted for new drug approval by the Drug Evaluation Center of the National Medical Products Administration of China as a treatment for moderate to severe vasomotor symptoms associated with menopause.”

by

2026-10-27 Astellas Pharma Inc. “VEOZA™ (fezolinenant) has been submitted for new drug approval by the D … 続きを読む

Sister site: Lagrange Financial News (Japanese-language)
Contact